Oden A - Search Results

1

The cost-effectiveness of risedronate in the UK for the management of osteoporosis using the FRAX.

Borgström F, Ström O, Coelho J, Johansson H, Oden A, McCloskey EV, Kanis JA. Borgström F, et al. Among authors: oden a. Osteoporos Int. 2010 Mar;21(3):495-505. doi: 10.1007/s00198-009-0989-8. Epub 2009 Jun 30. Osteoporos Int. 2010. PMID: 19565175

2

Intervention thresholds for osteoporosis in men and women: a study based on data from Sweden.

Kanis JA, Johnell O, Oden A, Borgstrom F, Johansson H, De Laet C, Jönsson B. Kanis JA, et al. Among authors: oden a. Osteoporos Int. 2005 Jan;16(1):6-14. doi: 10.1007/s00198-004-1623-4. Epub 2004 Apr 22. Osteoporos Int. 2005. PMID: 15103452

3

Cost effectiveness of raloxifene in the treatment of osteoporosis in Sweden: an economic evaluation based on the MORE study.

Borgström F, Johnell O, Kanis JA, Oden A, Sykes D, Jönsson B. Borgström F, et al. Among authors: oden a. Pharmacoeconomics. 2004;22(17):1153-65. doi: 10.2165/00019053-200422170-00005. Pharmacoeconomics. 2004. PMID: 15612833

4

FRAX Update.

Kanis JA, Harvey NC, Johansson H, Odén A, Leslie WD, McCloskey EV. Kanis JA, et al. Among authors: oden a. J Clin Densitom. 2017 Jul-Sep;20(3):360-367. doi: 10.1016/j.jocd.2017.06.022. Epub 2017 Jul 18. J Clin Densitom. 2017. PMID: 28732576 Review.

5

Effect and offset of effect of treatments for hip fracture on health outcomes.

Jonsson B, Kanis J, Dawson A, Oden A, Johnell O. Jonsson B, et al. Among authors: oden a. Osteoporos Int. 1999;10(3):193-9. doi: 10.1007/s001980050215. Osteoporos Int. 1999. PMID: 10525710

6

Cost-effectiveness of preventing hip fracture in the general female population.

Kanis JA, Dawson A, Oden A, Johnell O, de Laet C, Jonsson B. Kanis JA, et al. Among authors: oden a. Osteoporos Int. 2001;12(5):356-61. doi: 10.1007/s001980170102. Osteoporos Int. 2001. PMID: 11444082

7

The burden of hospitalised fractures in Sweden.

Johnell O, Kanis JA, Jonsson B, Oden A, Johansson H, De Laet C. Johnell O, et al. Among authors: oden a. Osteoporos Int. 2005 Feb;16(2):222-8. doi: 10.1007/s00198-004-1686-2. Epub 2004 Jul 1. Osteoporos Int. 2005. PMID: 15232678

8

Cost-effectiveness of raloxifene in the UK: an economic evaluation based on the MORE study.

Kanis JA, Borgström F, Johnell O, Oden A, Sykes D, Jönsson B. Kanis JA, et al. Among authors: oden a. Osteoporos Int. 2005 Jan;16(1):15-25. doi: 10.1007/s00198-004-1688-0. Epub 2004 Jul 24. Osteoporos Int. 2005. PMID: 15672210 Clinical Trial.

9

The use of multiple sites for the diagnosis of osteoporosis.

Kanis JA, Johnell O, Oden A, Johansson H, Eisman JA, Fujiwara S, Kroger H, Honkanen R, Melton LJ 3rd, O'Neill T, Reeve J, Silman A, Tenenhouse A. Kanis JA, et al. Among authors: oden a. Osteoporos Int. 2006;17(4):527-34. doi: 10.1007/s00198-005-0014-9. Epub 2006 Jan 10. Osteoporos Int. 2006. PMID: 16402164

10

Development and application of a Japanese model of the WHO fracture risk assessment tool (FRAX).

Fujiwara S, Nakamura T, Orimo H, Hosoi T, Gorai I, Oden A, Johansson H, Kanis JA. Fujiwara S, et al. Among authors: oden a. Osteoporos Int. 2008 Apr;19(4):429-35. doi: 10.1007/s00198-007-0544-4. Epub 2008 Feb 22. Osteoporos Int. 2008. PMID: 18292977 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

372 results

Search Page

Filters